Asset Details
Do you wish to reserve the book?
The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial
Do you wish to request the book?
The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial
2021
Overview
Background Iron overload‐induced oxidative stress and transfusion‐acquired hepatitis C virus (HCV) infection are the main reasons of liver damage in beta thalassemia major (β‐TM). Objectives Based on metformin’s hepatic benefits in nondiabetic populations, the study aims to investigate the safety and the potential hepatoprotective effect of metformin in HCV‐infected β‐TM adolescent patients. Methods This was a prospective, randomised, parallel, controlled, open‐label study in which 60 HCV‐infected β‐TM adolescent patients aged 11 to 18 years and receiving no antiviral therapy were selected and randomly assigned to treatment or control group in 1:1 allocation. Both groups were receiving β‐TM standard‐of‐care regimen, whereas metformin (500 mg, twice daily) was added to the treatment group's regimen only. Patients were prospectively followed up for 6 months with assessment of liver biochemical profile, oxidative stress markers, liver fibrosis, clinical symptom improvement and metformin's adverse effects. Results Aspartate aminotransferase serum level decreased significantly over time in the treatment group only (P = .013). However, improvement was not clinically significant and did not attain normality. Change in total antioxidant capacity and malondialdehyde serum levels indicated significantly improved oxidative stress status in the treatment group versus significant deterioration in the control group (P < .001). Fibrosis grade improvement was observed in 14 patients in the treatment group versus one improved case in the control group. Conclusion The use of metformin in HCV‐infected β‐TM adolescent patients as an adjuvant antioxidant hepatoprotective agent is promising and can improve liver damage.
Publisher
John Wiley & Sons, Inc
Subject
